He highlights how pricing information must be accessible and actionable—not just for health systems, but also for pharmacists and patients. With increased visibility driven by initiatives like the TrumpRx program, transparency is gaining momentum, but how medication information is delivered still needs significant improvement.
Lathe points out a key challenge: we’re not yet presenting pricing data in a way that truly helps providers and patients make informed decisions.
On the topic of women’s health, he notes the encouraging rise in attention and investment in topics like menopause, but emphasizes that education and affordability remain critical barriers. To truly move the needle, the industry must not only innovate, but ensure patients can access and understand the cost of care.
This conversation sheds light on the intersection of pricing, access, and equity in healthcare’s next chapter.